Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

AbbVie’s deal flop and NFL high-profile draft busts have a lot in common.

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

WASHINGTON — Newly empowered Republican leadership in the White House and in Congress will likely bring some good news and ...

Revenue: US$2.73m (down 33% from 3Q 2023). Net loss: US$162.0m (loss narrowed by 8.5% from 3Q 2023). US$0.86 loss per share ...

Investors increased their allocations to pharmaceuticals, banks, and industrials in November, according to the latest BofA ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma A/S has structured its capital to enable significant growth opportunities, with ...

With the respiratory illness season starting up in earnest, Vicks has reclaimed the top Rx and over-the-counter (OTC) pharma ...

The IPO of Onyx Biotec Limited was fully subscribed for within hours of its Wednesday, November 13 launch. There was a high ...

Urogen's UGN-102 presents a $5B market opportunity for bladder cancer treatment, despite risks. Read more about URGN stock ...

NSE's Nifty50 tumbled 324.40 points, or 1.36 per cent, to close at 23,559.05 for the day. Some buzzing pharma stocks ...

The deal is expected to provide SPIMACO with a significant opportunity to strengthen its product portfolio, enhance its ...